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Background: Magnetic fluids containing superparamagnetic iron oxide nanoparticles represent an attractive
platform as nanocarriers in chemotherapy. Recently, we developed a formulation of maghemite nanoparticles
coated with rhodium (II) citrate, which resulted in in vitro cytotoxicity enhanced up to 4.6 times when compared to
free rhodium (II) citrate formulation on breast carcinoma cells. In this work, we evaluate the antitumor activity and
toxicity induced by these formulations in Balb/c mice bearing orthotopic 4T1 breast carcinoma.
Methods: Mice were evaluated with regard to the treatments’ toxicity through analyses of hemogram, serum levels
of alanine aminotransferase, iron, and creatinine; DNA fragmentation and cell cycle of bone marrow cells; and liver,
kidney and lung histology. In addition, the antitumor activity of rhodium (II) citrate and maghemite nanoparticles
coated with rhodium (II) citrate was verified by tumor volume reduction, histology and immunohistochemistry.
Results: Regarding the treatments’ toxicity, no experimental groups had alterations in levels of serum ALT or
creatinine, and this suggestion was corroborated by the histopathologic examination of liver and kidney of mice.
Moreover, DNA fragmentation frequency of bone marrow cells was lower than 15% in all experimental groups. On
the other hand, the complexes rhodium (II) citrate-functionalized maghemite and free rhodium (II) citrate led to a
marked growth inhibition of tumor and decrease in CD31 and Ki-67 staining.
Conclusions: In summary, we demonstrated that both rhodium (II) citrate and maghemite nanoparticles coated
with rhodium (II) citrate formulations exhibited antitumor effects against 4T1 metastatic breast cancer cell line
following intratumoral administration. This antitumor effect was followed by inhibition of both cell proliferation and
microvascularization and by tumor tissue injury characterized as necrosis and fibrosis. Remarkably, this is the first
published report demonstrating the therapeutic efficacy of maghemite nanoparticles coated with rhodium (II)
citrate. This treatment prolonged the survival period of treated mice without inducing apparent systemic toxicity,
which strengthens its use for future breast cancer therapeutic applications.* Correspondence: marbretas@gmail.com
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Breast cancer represents the main cause of death in
women worldwide due to the high metastatic capacity of
this disease [1]. Nowadays, chemotherapy is the most
commonly used treatment in the therapeutic approach;
however, conventional chemotherapy has shown low ef-
ficacy when the disease is not treated in early stages [2].
As a matter of fact, chemotherapy drugs are not specific
and act both on tumor and normal cells, causing side
effects [3]. Thus, the development of therapeutic strat-
egies such as drug delivery systems (DDS) represents an
area of great interest in cancer research [4-6].
Through the development of nanotechnology,
nanomaterials designed to work as DDS are increasingly
being used in nanomedicine. This field has advanced,
presenting innovative approaches, allowing the improve-
ment of cancer therapeutic treatments [7]. Among vari-
ous materials used for DDS, magnetic fluids containing
superparamagnetic iron oxide nanoparticles (SPIOs) repre-
sent an attractive platform as nanocarriers in chemotherapy
[8]. SPIOs ranging from 10 to 500 nm in size can accumu-
late inside the interstitial space in tumors, since the blood
vessel wall becomes more permeable than in the normal
tissue state. This effect, added to the poor lymphatic drain-
age in tumor and the tumor microvasculature, which has a
discontinuous and loose nature [9,10], is known as
enhanced permeability and retention (EPR) and is currently
considered an effective way to bring drugs into tumors, es-
pecially drug-loaded nanocarriers [11]. Thus, SPIOs have
shown promising results in the field of oncology, acting as
an efficient DDS for controlled drug release and penetra-
tion in solid tumors [4,7,12].
In the last decade, an increasing number of investigations
using several types of iron oxide-based nanoparticles have
been carried out [13]. However, only maghemite (γ-Fe2O3)
and magnetite (Fe3O4) are able to fulfill the necessary
requirements for biomedical applications, due to their su-
perior biocompatibility with respect to other magnetic
materials [14]. Nowadays, magnetic nanoparticles are being
associated with several chemotherapy drugs, such as
doxorubicin [15], docetaxel [16], methotrexate [17], tamoxi-
fen [18], paclitaxel and cisplatin [19].
Rhodium carboxylates, a class of metal complexes, have
shown promising antitumor activity in cisplatin-resistant
cell lines [20]; they present significant cytostatic activity in
tumors L1210, Ehrlich ascites carcinoma, sarcoma 180 and
P388 and melanoma B16 [21]. Among the class of rhodium
carboxylates, rhodium (II) citrate showed cytotoxic activity,
cytotoxic and antitumor Ehrlich breast carcinoma [22].
Interestingly, the citrate ligand of this complex has the abil-
ity to functionalize SPIOs to promote stability and biocom-
patible stable colloidal suspensions, making them suitable
for applications in drug delivery systems. Whereas the
maghemite nanoparticle surface is easily functionalized byions or molecules, the free carboxyl groups, present in the
chemical structure of rhodium (II) citrate, can bind to Fe-
OH surface of nanoparticles, a reaction that occurs with
the elimination of water and formation of the Fe-OCO
chemical bond (Figure 1).
Recently, our group developed a formulation of
maghemite nanoparticles (NPs) coated with citrate
(Magh-cit) and rhodium (II) citrate (Magh-Rh2(H2cit)4),
and we have shown that Magh-Rh2(H2cit)4 enhanced cyto-
toxicity on breast carcinoma cells by up to 4.6 times when
compared to free rhodium (II) citrate (Rh2(H2cit)4). Like-
wise, we verified that Magh-Rh2(H2cit)4 induced higher
in vitro cytotoxicity on breast carcinoma cells than on
breast normal cells [23]. Thus, in the present study, we
aimed to evaluate the antitumor activity and systemic
toxicity induced by intratumoral injections of Rh2(H2cit)4
and Magh-Rh2(H2cit)4 in Balb/c mice bearing 4T1 breast
carcinoma.Results and discussion
Systemic toxicity assessment in mice bearing 4T1 breast
carcinoma
No skin ulceration, weight loss or evident alterations
were found, indicating the good tolerance of mice to the
treatments. There were also no significant differences in
the analyzed hematological parameters when Rh2(H2cit)4
and Magh-Rh2(H2cit)4 groups were compared with the
control (Table 1). The evaluation of blood cells is an in-
tegral part of the routine assessment of healthy and dis-
eased animals [24]. Moreover, combining hematology
analysis with biochemical serum dosages, we have an
important tool for pathologic analysis.
No experimental groups had alterations in levels of serum
ALT or creatinine. This suggestion was corroborated by the
histopathologic examination of liver and kidney of treated-
mice (Figure 2), which showed no morphological changes,
although a focal inflammatory infiltrate in the liver was
observed (Figure 2D, 2G, 2J, and 2M) from mice bearing
4T1 breast carcinoma. However, this is a benign reaction,
known as an inflammatory pseudotumor (IPT) that has
been described in both sexes, at all ages, and in almost any
location. IPTs are the expression of diverse inflammatory
processes of unknown etiology that may be accompanied
by a tumor-like mass and affect several organs of the body.
Although the usual location of IPT is the lung, the most
common extrapulmonary site of IPT is the liver [25]. Thus,
the results indicate that this focal inflammatory infiltrate
was a liver response to tumor implantation, since no
nanoparticles were observed in the analyzed organs.
Evaluation of the potential genotoxic effects on normal
cells is crucial during the development of new anticancer
drugs in order to avoid severe DNA damage to non-
targeted cells [26]. DNA fragmentation frequency of BM
Figure 1 Representation of rhodium (II) citrate showing chemical bond between rhodium (II) citrate and maghemite nanoparticles.
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with the Magh-Rh2(H2cit)4 group showing DNA very
similar fragmentation frequency to the control group,
and Rh2(H2cit)4 and Magh-citrate groups showing
slightly higher values (Figure 3A). No significant differ-
ence in the BM cell cycle was observed among the
groups (Figure 3B). Thus, the results indicate that Magh-
Rh2(H2cit)4 treatment did not lead to significant interfer-
ence in DNA integrity or cell division of BM cells in mice.
The present data are corroborated by previous reports
showing that no genotoxic effects were observed in
mice treated with nanoparticle formulations containing
maghemite, cobalt ferrite or magnetite [27-29].Table 1 Effects of Rh2(H2cit)4, Magh-Rh2(H2cit)4 and Magh-citr
female Balb/c mice 23 days after animals’ tumor transplantat
Treatment Control Rh2(H
Hematology parameters
WBC (/mm3) 18445.50± 6020.68 24555.00
RBC (x109/mm3) 8.69±0.27B 10.82
HGB (g/dL) 13.60±0.42 14.75
HCT (%) 41.60±1.38 44.62
Lymphocytes (%) 28.75±6.65 38.50 ±
Rods (%) 1.25±1.25 0.50 ±
Segmented (%) 67.00±7.14 57.67 ±
Eosinophils (%) 0.00±0.00 0.00 ±
Basophils (%) 0.25±0.25 0.17 ±
Monocytes (%) 2.75±0.75 3.17 ±
Biochemical parameters 25.20±6.22 25.50
ALT (U/L) 0.10±0.00 0.10 ±
Creatinine (mg/dL) 125.60±18.59 143.67
Serum Fe (mg/dL)
Legend: WBC (White Blood Cells); RBC (Red Blood Cells); HGB (Hemoglobin); HCT (H
1Values are represented as mean ± standard error.
Note: all treatments have no statistical difference when compared with untreated cTumor volume regression and survival test
The complexes rhodium (II) citrate-functionalized
maghemite (Magh-Rh2(H2cit)4) and free rhodium (II) citrate
(Rh2(H2cit)4) led to a marked growth inhibition of tumor,
when compared to the control group (p<0.05). These
treatments induced a significant tumor volume reduction of
about 75% and 52%, respectively, which demonstrated effi-
cient antitumor activity of these complexes on the 4T1
metastatic breast cancer cell line (Figure 4A). Antitumor
effects were not observed in mice treated with citrate-
functionalized-maghemite (data not shown).
Citrate-functionalized-maghemite has been attested as
providing successful nanoparticles in the production ofate on hematology and biochemical parameters of
ion1
2cit)4 Magh-Rh2(H2cit)4 Magh-citrate
± 9693.69 45774.00 ± 11995.51 59060.00 ± 25390.07
± 1.19 10.07 ± 1.03 10.17 ± 0.86
± 0.33 14.26 ± 0.14 13.36 ± 0.85
± 0.96 44.40 ± 0.39 41.09 ± 2.51
13.88 10.80± 3.35 18.71 ± 7.66
0.50 0.00 ± 0.00 1.43 ± 0.65
13.40 84.00 ± 3.36 70.57 ± 7.40
0.00 0.00 ± 0.00 0.14 ± 0.14
0.17 0.00 ± 0.00 0.14 ± 0.14
1.01 5.20 ± 1.11 9.00 ± 4.94
± 3.57 20.86 ± 2.15 21.33 ± 3.38
0.00 0.10 ± 0.00 0.13 ± 0.02
± 14.22 127.57 ± 12.10 112.33 ± 15.23
ematocrit); ALT (alanine transaminase).
ontrol mice (P>0.05).b.
Figure 2 (See legend on next page.)
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Figure 2 Representative histopathology of liver, kidney and lung from Balb/c mice healthy and Balb/c mice bearing 4T1 breast
carcinoma in different treatment groups. The animals were treated with Rh2(H2cit)4 and Magh-Rh2(H2cit)4 (1050 μM total dose equimolar of
Rh2(H2cit)4), and they were sacrificed on the 23
rd day after tumor inoculation. Tumor sections were stained with H&E. A-C) Healthy mice and mice
bearing 4T1 breast carcinoma without treatment (D-F) or treated with Rh2(H2cit)4 (G-I), Magh-Rh2(H2cit)4 (J-L) and Magh-citrate (M-O).
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our work was the first to investigate and demonstrate the
antitumor effect of rhodium (II) citrate associated with
nanoparticles on in vivo 4T1 orthotopic breast carcinoma
model. Previous studies, conducted by Zyngier et al
(1989), demonstrated that free rhodium (II) citrate has sig-
nificant antitumor, cytotoxic, and cytostatic activity in
Swiss mice bearing ectopic breast carcinoma model
(Ehrlich cell line) [22], which is in agreement with our
results.
Nevertheless, two important aspects should be taken
into consideration. First, unlike the study of Zyngier et al
(1989), where the process of tumor implantation was
ectopic, we transplanted tumor cells in the mammary
gland (orthotopic implantation), which is the original en-
vironment of this cell line. This represents an important
factor when developing therapies that are able to target
not only the tumor but also its microenvironment
components [32]. In view of this, our results are of great
importance for the study of the effects of anticancer
drugs in the mammary microenvironment. Second, our
study is the first to evaluate in vivo the effects of the
association of rhodium (II) citrate to nanoparticles. We
suppose that these associations could provide higher
therapeutic efficacy than free formulations, since drug-
loaded nanocarriers potentially provide controlled time
release of the drug beyond modification of drug pharma-
cokinetics and biological distribution [33]. Moreover,
the interaction of nanoparticles with the biologicalFigure 3 Toxicity of Rh2(H2cit)4 and Magh-Rh2(H2cit)4 on bone marrow
treated with Rh2(H2cit)4 and Magh-Rh2(H2cit)4 with seven equimolar doses
marrow cells were stained with propidium iodide and analyzed by flow cyt
percentages as mean ± SEM. Different letters indicate significant differenceenvironment is very important for designing strategies
that should be selective at the pharmacological site,
especially in the breast, where the blood flow and lymph-
atic drainage is intense [34].
Furthermore, we also evaluated the antitumor effect of
Rh2(H2cit)4 and Magh-Rh2(H2cit)4 by the survival ana-
lysis of mouse groups, during the experimental period of
23 days. Deaths in the mouse control group (with un-
treated tumors) started on experimental day 16 after
tumor implantation. On the 18th and 21st days, two
deaths occurred in each group of animals treated with
Rh2(H2cit)4 or Magh-citrate, and one death in the con-
trol group. All mice in the Magh-Rh2(H2cit)4 group
survived until the end of the experimental period (23 -
days) (Figure 4B). Magh-Rh2(H2cit)4 complex exhibited
antitumor effect against 4T1 metastatic mouse breast
carcinoma, without apparent systemic toxicity and a sig-
nificant increase in treated mice survival period (period
of 23 days). Zyngier and Kimura (1989) showed a per-
centage of 78.8% survival in Swiss mice treated with Rh2
(H2cit)4 after implantation of Ehrlich tumor cells, in a
period ranging from 23 to 27 days [22]. These findings
are consistent with the present study since we observed
the same survival percentages in Balb/c mice treated
with free Rh2(H2cit)4 (about 75%), after 4T1 cell im-
plantation for a similar period of time (Figure 4B).
In our previous study, we reported that Rh2(H2cit)4
induced cytotoxicity on both breast cancer and breast
normal cells, in vitro. However, rhodium associated withcells of mice-bearing 4T1 breast carcinoma. Mice (n=8) were
of Rh2(H2cit)4 (1050 μM total dose) until 23rd day. Subsequently, bone
ometry. (A) DNA fragmentation (B) Cell cycle. Data were expressed as
among experimental groups (p<0.05).
Figure 4 Antitumor effect and survival curve. The mice were treated with Rh2(H2cit)4 or Magh-Rh2(H2cit)4 and received seven equimolar doses
of Rh2(H2cit)4 (1050 μM total dose) until 23rd day after tumor inoculation. A) Antitumor effects of Rh2(H2cit)4 and Magh-Rh2(H2cit)4. B) Survival
curve for tumor-bearing mice. Values represent mean values ± standard error (n=8/each group) and different letters indicate statistical difference
among treatments (p<0.05).
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toxic to breast cancer cell lines [23]. These findings are
consistent with the present in vivo study since mice
treated with Magh-Rh2(H2cit)4 showed a decrease in
tumor volume, without occurrence of deaths or macro
and microscopic alterations.
Although rhodium (II) citrate-coated maghemite
nanoparticles have never been described before, another
study reported the association of rhodium (II) citrate with
hydroxypropyl-beta-cyclodextrin, macrocyclic oligosugars
from biodegradable polymer. In this study, the association
with these oligosugars led to the minimization of
nonspecific toxicity since they increased the efficiency of
encapsulation and the duration of rhodium (II) citrate re-
lease [35].
On the other hand, some strategies have been used to
increase the specificity of antitumor agents by associat-
ing drugs with nanocarriers. SPIOs, for instance, are
considered one of the most important nanocarriers due
to their inherently low particle size, high magnetization
values and ability to load anticancer agents, allowing
enhanced therapeutic selectivity provided by local hyper-
thermia, magnetic targeting and magnetic resonance im-
aging [36,37]. Furthermore, SPIOs are small enough to
escape renal clearance and opsonization processes, thus
being able to accumulate easily in the tumor [38]. The
Magh-Rh2(H2cit)4 complex used in this study contains
nanoparticles with sizes of 10 nm [23] thus being small
enough to escape renal clearance and opsonization
processes, which can promote a preferential accumulation
in the tumor due to its abnormal vascular nature [38].
Hence, the nano-sized property was exploited to take ad-
vantage of alterations that occur in tumor cells and adja-
cent tissues [39].
Tumor histopathology
Histological analyses showed that the 4T1 tumor model
without treatment was invasive and characterized by
typical and atypical mitoses, poor differentiation,moderate pleomorphism with neovascularization areas
and infiltration of inflammatory cells in tissue (data not
shown). Previous reports showed that 4T1 tumor cells
display a multistage tumor development pattern with
atypical hyperplasia [40], corroborating our findings.
The 4T1 orthopic breast tumor is a model that shares
similarities with metastatic human breast cancer, thus
representing a good model to evaluate the efficacy of
anticancer drugs [41].
Histopathological characteristics of the different treat-
ment groups are shown in Figure 5. Tumors from
control groups (control and Magh-citrate) presented pe-
culiar pleomorphism and were characterized as poorly
differentiated. Moreover, in mice treated with Rh2(H2cit)
4 we observed inflammatory edema (Figure 5E), as well
as the presence of nuclear fragments observed in both
Rh2(H2cit)4 and Magh-Rh2(H2cit)4 groups, which may be
related to tumor cell death by apoptosis (Figure 5D, I).
These results corroborate the tumor regression observed
in mice treated with these compositions.
Regarding Rh2(H2cit)4 and Magh-Rh2(H2cit)4 treatments,
we observed intense necrosis and fibrosis, demonstrating
that its antitumor effectiveness can be associated with cell
death triggered in tumor tissue (Figure 5F-H). Moreover, in
mice treated with Rh2(H2cit)4 we observed inflammatory
edema (Figure 5E), as well as the presence of nuclear
fragments observed in Rh2(H2cit)4 and Magh-Rh2(H2cit)4
groups, which may be related to tumor cell death by apop-
tosis (Figure 5D, I). These results corroborate the tumor re-
gression observed in mice treated with these compositions.
In Figure 6A the control group tissue is shown, where
no nanoparticles were found, while in Figure 6F a posi-
tive control is shown for Perls staining in human tissue.
We demonstrated the presence of nanoparticles (Magh-
Rh2(H2cit)4 and Magh-citrate) on tumor tissue, suggesting
that these complexes were uptaken by tumor cells
(Figure 6B-E). It has been reported that the accumulation
of nanoparticles in cancer cells is useful not only for can-
cer detection and treatment but also essential to the
Figure 5 Representative histopathology of mammary gland and tumors developed from Balb/c mice bearing 4T1 breast carcinoma in
different treatment groups. The animals were treated as described in section 2.3 and tumor slides were stained with H&E. A) Healthy group. B)
Control. C) Magh-citrate. D-F) Rh2(H2cit)4. G-I) Magh-Rh2(H2cit)4. Asterisk indicates changes in the glandular epithelium tumor. Duct (D). Fibrosis
(F). Lymph node (Li). Necrosis areas (N). Secretion (S). Tumor (T). Vessel (V). Apoptosis cells (arrows).
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face chemistry and charge have an intense effect on its in-
ternalization capability in cells [43]. Previous studies have
demonstrated that anionic magnetic nanoparticles are
taken up by smooth muscle cells [44], RAW 264.7 mouse
macrophages, human cervix adenocarcinoma cell line,
HeLa and melanoma cells [45] by intracytoplasmic
vesicles [46]. It is of note that this internalization is re-
sponsible for the observed biological effects. We suggest
that tumor regression in mice treated with Magh-Rh2
(H2cit)4 is correlated to the internalization of these
complexes by tumor cells, and consequent tumor injury
observed in our histopathological analysis.
CD31 and Ki-67 immunohistochemistry analysis
We observed that administration of Rh2(H2cit)4 and
Magh-Rh2(H2cit)4 led to significant decrease of CD31 and
Ki-67 staining compared with controls (Figures 7 and 8),
corroborating many studies that have associated the re-
duction of Ki-67 and CD31 molecules with the efficacy ofantitumor agents [40,47].The treatments with Rh2(H2cit)4
and Magh-Rh2(H2cit)4 showed a pronounced reduction of
up to 50% in the number of Ki-67 positive cells (Figure 7E).
Ki-67 is a nuclear protein linked to the cell cycle and a cell
proliferation marker that has predictive and prognostic
value in breast cancer patients [48], thus improving the
understanding of the drug response. We suggest that
Ki-67 reduction induced by Rh2(H2cit)4 and Magh-Rh2
(H2cit)4 is associated with the tumor growth suppression
observed in these treatments.
High levels of CD31 (angiogenesis marker) are corre-
lated with poor prognosis and decreased survival of breast
cancer patients [49]. Studies demonstrated that during
prostate cancer treatment with cryoablation a positive
correlation between necrosis and hypoxia and negative
correlation with microvessel density was observed through
the decrease in CD31 expression and the increase in
necrosis area [50]. Further, another study demonstrated
that tumor growth delay is associated with decrease in
microvessel density and increase in tumor cell apoptosis
Figure 6 Histopathology of mammary gland and tumors developed from Balb/c mice bearing 4T1 breast carcinoma in different
treatment groups. The animals were treated as described in section 2.3 and tumor slides were stained with Perls coloration. A) Breast tissue of
healthy group. B) 4T1 tumor cells without treatment (control), with treatment of Rh2(H2cit)4 (C), Magh-Rh2(H2cit)4 (D) and Magh-citrate (E). F)
Positive control staining Perls Prussian blue (human tissue). The blue-green indicates Fe2+ (iron is non-oxidized) and brown indicates the presence
of Fe3+ (oxidized iron). The presence of maghemite nanoparticles (oxidized iron) was observed, represented by brown coloration.
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important since they are correlated with the metastasis
process [52] and cell death [53].
Histopathological analysis showed numerous necrosis
areas and low Ki-67 and CD31 expression in 4T1 tumor
tissues treated with Rh2(H2cit)4 and Magh-Rh2(H2cit)4.
Therefore, we suggest that the antitumor efficacy of these
formulations is correlated with a reduction in Ki-67 and
CD31 molecules, which indicates a decrease in both the
cellular proliferation and microvessel network develop-
ment. Overall, the histopathology, immunohistochemistry
and regression tumor findings are consistent and linked.
Conclusion
In summary, we demonstrated that both Rh2(H2cit)4
and Magh-Rh2(H2cit)4 formulations exhibited antitumor
effects against 4T1 orthotopic breast cancer cell line
following intratumoral administration. This antitumor ef-
fect was followed by inhibition of both cell proliferation
and microvascularization and by tumor tissue injurycharacterized as necrosis and fibrosis. Remarkably, this is
the first published report demonstrating the therapeutic
efficacy of Magh-Rh2(H2cit)4. This treatment prolonged
the survival period of treated mice without inducing ap-
parent systemic toxicity, which strengthens the case for its
use in future breast cancer therapeutic applications.
Methods
Preparation of the rhodium (II) citrate and rhodium (II)
citrate-loaded maghemite nanoparticles
The maghemite nanoparticles (Magh-citrate) and rhodium
citrate, Rh2(H2cit), as well as the rhodium(II) citrate-loaded
superparamagnetic iron oxide nanoparticles (Magh-Rh2
(H2cit)4), (Figure 1) were prepared and characterized
as previously described [23]. Briefly, Rh2(H2cit)4 was
synthesised by exchange trifluoroacetate ligands from the
precursor rhodium(II) trifluoroacetate by citrate ligands.
The compound was obtained as a green aqueous solution
with a standardised concentration of 0.054 mol L-1.
Maghemite nanoparticles were synthesised by alkaline co-
Figure 7 Inhibition of cell proliferation (Ki67) in 4T1 breast carcinoma tissue. The mice were treated as described in section 2.3 and tumor
slides were immunostained with anti-Ki67. A) Control, B) Magh-citrate, C) Rh2(H2cit)4 D) Magh-Rh2(H2cit)4. E) Quantification of Ki67 staining
indicated that treatments with Rh2(H2cit)4 and Magh-Rh2(H2cit)4 inhibited tumor cell proliferation by nearly 50% within solid tumor sections when
compared to untreated control mice. Data represent mean values ± standard error (n=4/each group) and different letters indicate statistical
difference among treatments (p<0.05).
Carneiro et al. Journal of Nanobiotechnology 2013, 11:4 Page 9 of 13
http://www.jnanobiotechnology.com/content/11/1/4precipitation of Fe2+ and Fe3+ ions. The particles obtained
in the magnetite (Fe3O4) phase were oxidised to maghemite
(γ-Fe2O3) by bubbling of oxygen gas and were subsequently
purified by dialysis with deionised water for several days
([Fe] = 0.37 M). The Magh-Rh2(H2cit)4 was prepared using
5 mL of the colloidal dispersion with 1 mL of Rh2(H2cit)4
and stirred for 24 hours.Orthotopic tumor cell implantation and treatment
Balb/c female mice (12 weeks old) were purchased from
Cemib-UNICAMP (São Paulo, Brazil). All mice were
maintained in plastic cages under standard conditions
of 12 h dark/light cycle. The mice, weighing 20–25 g, were
fed with standard diet and water ad libitum. All
experiments described were approved by the Animal
Figure 8 Effect of Rh2(H2cit)4 and Magh-Rh2(H2cit)4 in inhibition of CD31 on mammary gland from Balb/c mice bearing 4T1 breast
carcinoma in different treatment groups. The animals were treated as described in section 2.3 and tumor slides were immunostained with
anti-CD31. A) Control, B) Magh-citrate, C) Rh2(H2cit)4 D) Magh-Rh2(H2cit)4.
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The 4T1 breast carcinoma cells were thawed and
cultivated in flasks with Dulbecco’s modified eagle’s
medium (DMEM) supplemented with 1% penicillin and
10% fetal bovine serum (FBS) at 37C in a humidified
atmosphere 5% CO2. Two weeks later, Balb/c mice were
anesthetized with ketamine (80mg/kg) and xilazin (10
mg/kg) via intraperitoneal. Then, 2×104 4T1 cells (in sus-
pension in 50 μL serum-free DMEM) were injected
(1mL-gauge needle) in their mammary gland, which is
the natural primary microenvironment of breast tumor
occurrence. Seven days after implantation of 4T1 cells,
mice were divided into four groups (n=8/group), and each
group was treated with 50 μL of (1) Rh2(H2cit)4, (2) Magh-
Rh2(H2cit)4, (3) Magh-citrate or (4) water. Peritumoral
injections were carried out every three days, totalizing
seven applications of 0.3 mg/kg rhodium (II) citrate (total
dose of Rh2(H2cit)4 was 2mg/kg).
Mice treated with Magh-citrate received the same iron
concentration and nanoparticle amount found in Magh-
Rh2(H2cit)4 (0.37M and 2.4×10
15 particles). Animals
without tumor and without treatment (healthy) were
also included in this study as control groups. On the
23rd experimental day after tumor implantation, themice of each experimental group were euthanized and
the tumor, liver, kidney, and lung were collected to
perform antitumor and systemic toxicity analysis as
described in items 2.4, 2.5 and 2.6.
Systemic toxicity assessment in mice bearing 4T1 breast
cancer
In order to evaluate potential systemic toxicity induced
by the treatments, analyses of macroscopic aspects,
histology, blood, DNA fragmentation and cell cycle were
performed. Treated mice were continuously monitored
for relevant indexes such as weight loss, diarrhea, skin
ulcers and deaths.
Before euthanasia, which was by cervical dislocation,
animals were anesthetized with the mixture of xylazine
and ketamine described previously (item 2.3). Blood
samples (1mL/animal) collected by cardiac puncture were
used to carry out hemogram and biochemical dosages
of serum alanine aminotransferase (ALT), iron and
creatinine. Hemogram was processed in a multiple
automated hematology analyzer (XZ 2100 Sysmex equip-
ment) and serum biochemical analyses were run on the
automated chemistry analyzer ADVIA 2400 (Siemens),
using the appropriate Advia chemistry reagents, protocols
and controls.
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collected from femurs and resuspended in one milliliter
of fetal bovine serum (FBS, Gibco) to perform DNA
fragmentation and cell cycle analyses, which is a rapid
detection method of chromosome damage and interfer-
ence with cell mitosis caused by several agents [54].
Cells were fixed in cold 70% ethanol, and stored over-
night at -30°C. The cells were centrifuged and incubated
with 300 μL of lysis buffer (0.1% sodium citrate, 0.1%
Triton X-100 and 20 μg/mL of propidium iodide, diluted
in PBS pH 7.4) for 30 min at room temperature and
protected from light. DNA fragmentation and the cell
cycle were analyzed using FACS Calibur flow cytometry
(Becton & Dickenson, USA) and a total of 10,000 events
were collected per sample. Histopathology analysis of
the liver, kidneys and lungs was also performed in order
to verify possible toxic effects induced by treatments.
Tumor regression and survival analysis
To evaluate tumor regression, tumors were surgically
removed, their width and length measured by a digital
pachymeter (Stainless, hardened), and their respective
volumes calculated according to the formula of Yanase
et al. (1998): length × width2 × 0.52 [55]. Animals that
had died were submitted to necropsy, and the time of
their death was recorded.
Histopathology and immunohistochemistry analysis
Tumors were fixed in 10% phosphate-buffered formalin
overnight (room temperature), transferred to 70% etha-
nol, included in paraffin using an automatic tissue pro-
cessor (OMAW DM-40, São Paulo, Brazil), cut to 5 μm
of thickness in a Leica RM2235 manual microtome
(Leica Microsystems, Nussloch, Germany) and stained
with hematoxilin-eosin (HE) or Perls Prussian Blue
for histological analyses (light microscopy). Histological
sections were examined to verify the presence of
nanoparticles, cell proliferation pattern, pleomorphism,
degree of cell differentiation and cell death.
Immunohistochemical analyses were performed in order
to analyze cell proliferation by Ki-67 staining and
vascularization by CD31 staining in the tissues. After
paraffin removal and hydration, histological sections were
immersed in citrate buffer (3mM, pH 6.0) for 10 minutes
at 120°C for antigen retrieval. Subsequently, non-specific
binding sites were blocked with 3% normal serum or BSA.
Afterward, the sections were incubated with anti-Ki-67
(1:200 Abcam, ab15580) or CD31 antibodies (1:200 Dako,
K4067, Glostrup, Denmark) for 2 h at room temperature,
washed and then incubated with biotinylated secondary
antibodies for 20 min followed by avidin-biotin complex
(LSAB-HRP Kit, Dako, K0690, Glostrup, Denmark). After
washing, sections were incubated with diaminobenzidine
substrate and counterstained with Mayer's hematoxylin.All cells were counted in five consecutive microscopic
high power fields (400x) using an integration graticule
(CARL ZEISS-4740680000000-Netzmikrometer 12.5×).
At this magnification, each field has an area equal to
0.015625mm2; thus a total area equal to 0.078125mm2
was analyzed in each specimen.
Statistical analysis
To evaluate differences in tumor volume in each experi-
mental group, after the treatments in Balb/c mice
bearing 4T1 breast carcinoma, the following tests were
run: inhibition of cell proliferation (by quantification of
positive Ki67 staining cells number) in 4T1 breast car-
cinoma tissue; levels of serum ALT, creatinine and iron
and peripheral blood counts (in order to verify the sys-
temic effects of the treatments with Rh2(H2cit)4 and
Magh-Rh2(H2cit)4); and in the proportion of DNA frag-
mentation or the cell cycle phase number of bone mar-
row of mice, the one-way Analysis of variance (ANOVA)
was performed. When statistically significant differences
were found, analysis was complemented by the Tukey
test or the Bonferroni method. Before the intragroup
comparison, the Shapiro Wilk test was conducted, to
check whether each variable was normally distributed.
Between-group comparisons of weight on different days
after tumor transplantation were performed using a two-
way ANOVA with post-hoc Dunnet test.
To describe the survival prolongation effect after the dif-
ferent treatments in Balb/c mice bearing 4T1 breast car-
cinoma, the Kaplan-Meier statistical method was used to
generate survival curves. Then, these survival curves were
compared using the Mantel-Haenszel log-rank test.
Data were presented as means ± SE. The significant
level adopted was 5%. Calculations were done using the
SPSS, Inc., Chicago, IL software (version 17.0). All plots
were generated using GraphPad Prism 5.0 (GraphPad
Software, La Jolla, Calif.).
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